TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Success of treatment defined as vaccination-induced T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute GvHD of Grade III or higher or extensive chronic GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Time to admission to neurosurgical department
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of proximal extension of DVT and/or pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Post-traumatic headache recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak transaminase value post transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Increase in Prostate-specific Antigen (PSA) Doubling Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Numeric Pain Scale (Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oswestry Back Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in orthostatic tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum drug levels of nortriptyline or venlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Degree of Disability/Dependence as Measured by the Modified Rankin Scale (mRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neuropathic pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time Per Patient From a Clinical Event to a Clinical Decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful endoscopic resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Unexpected device performance
Endpoint domain: Adverse events/effects
Primary endpoint: Complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse device events
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to treatment duration protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: days at home up to 30 days after surgery
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from Baseline in Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in OQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Log 10-transformed HIV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median Recurrence Free Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: Use of iron-folic acid supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of calcium supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary diversity during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary micronutrient intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coverage of maternal nutrition intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intensity of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive metacholine test (bronchial hyperreactivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bispectral Index (BIS) Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroblast growth kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pain Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of mefloquine in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of denufosol injections
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of denufosol for retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Zinc Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Selenium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reproducibility of Sinonasal Outcome test 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with switching between clopidogrel and ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with switching between clopidogrel and ticagrelor without a reloading dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with discontinuation of P2Y12 receptor antagonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with ticagrelor combined with other anticoagulants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalisation and Nursing Home Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Serum hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Clinical score of site and severity of infection and inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: non detectable HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune T cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of BMD (Bone mineral density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fever >= 100.4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hopkins Verbal Learning Test (HVLT) Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: D2-induced change in 25(OH)D3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: D3-induced change in 25(OH)D2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: manuscript letter legibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: script letter legibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: manuscript transcription speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: script transcription speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total width of the buccolingual bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infra-orbital nerve enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage change of RANKL/OPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genes with logarithm of odds (LOD) > 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nevi Estimated Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SCORAD Change Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients With Testosterone <=0.5 Nanograms/Milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Psoriasis disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of communication strategies by clinicians
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PDD Behavior Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Feasibility Criteria Successfully Met
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Right Heart - Tricuspid annular plane systolic excursion (TAPSE), change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Heart - RV fractional area change, change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Heart - longitudinal myocardial velocity (S'), change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Educational achievement as assessed by report cards
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Educational achievement as assessed by CAT4 scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Educational achievement as assessed by EQAO scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tpe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tpe/QT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tpe/QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plasma PBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurobehavioural Cognitive State Examination (NCSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rivermead Behavioural Memory Test (RBMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence or absence of macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevalence of novel oral anticoagulants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contamination of the operation area
Endpoint domain: Adverse events/effects
Primary endpoint: Post-intervention daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confidence level in therapeutic decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average number of steps taken per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Any Clinical Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Participants Discontinued Because of Any Clinical Adverse Experience
Endpoint domain: Adverse events/effects
Primary endpoint: Weight Dissipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR+near CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin fragments (F1+2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Attrition to trial sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parents' Interest in the SBIRT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parents' Uptake of the SBIRT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Heart size and function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in serum MTX concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in EEG microstates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline on Cleveland Clinic Constipation Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline on the St. Mark's Fecal Incontinence Grading System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DHA-Containing Phosphatidylcholine Species in Circulating Erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Saturation level during the test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational Rhinitis symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Intra-cranial objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: radiation side effects
Endpoint domain: Adverse events/effects
Primary endpoint: HCV-specific T cell phenotype and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: glycemic values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local muscle oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in characteristics of lesion within the vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in mean daily physical activity level (PAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daily energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum voluntary knee extension torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Confidence in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain interference: PROMIS- Pain interference Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor to Background Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: relative adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Short Physical Performance Battery (SPPB) Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Isometric Hand Grip Strength (IHGS) Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics profile of BAY79-4620
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Surgical Levels With Successful Lumbar Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of EULAR responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical relapse free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Successful Completion of Preoperative Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Characterization of immune abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evaluation of organ dysfunction/damage resulting from immune abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circularity of created rhexis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Seroprotection for Measles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Analgesia requirements
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of retroprosthetic membrane formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Rate of glaucoma development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Induction Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of NRT (Nicoderm patches)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all cause hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Return home rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage residing at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Hospital complications of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of quadriceps atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Per Lesion Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Per Lesion Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pre-operative Patient Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients exhibiting SPD alert
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Neurological Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of appropriate thromboprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Skin and muscle Na+ content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Antibody Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Required Supplementation of Local Anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount (ml) of Local Anesthetic Supplemented by Surgeon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lymphedema volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper limb function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: qEEG gamma band activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HBeAg seroconversion to anti-HBe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Grade II-IV Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Global assessment of hemostatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of non-surgical bleeding episodes per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of Voncento® needed to treat a non-surgical bleeding episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI-z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotide-femoral pulse velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upper Limb Motor Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Functional Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain and Disability of the Foot and Ankle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total Sleep time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasodilator Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of acute respiratory infection visits treated with antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients using alternative medicine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cmax of EDP-305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of EDP-305
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle relocation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular reverse remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in neurocognitive assessment performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Satisfactory Humoral Response to the Pneumococcal Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfactory Humoral Response to the Seasonal Influenza Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive function as measured by ADAS-Cog-C
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning